MCID: LNG039
MIFTS: 57

Lung Squamous Cell Carcinoma

Categories: Cancer diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Lung Squamous Cell Carcinoma

MalaCards integrated aliases for Lung Squamous Cell Carcinoma:

Name: Lung Squamous Cell Carcinoma 12 15
Squamous Cell Carcinoma of Lung 12 70
Squamous Cell Lung Carcinoma 6 17
Epidermoid Cell Carcinoma of the Lung 12
Squamous Cell Lung Cancer 54

Classifications:



External Ids:

Disease Ontology 12 DOID:3907
NCIt 50 C3493
SNOMED-CT 67 254634000
UMLS 70 C0149782

Summaries for Lung Squamous Cell Carcinoma

Disease Ontology : 12 A non-small cell lung carcinoma that has material basis in the squamous cell.

MalaCards based summary : Lung Squamous Cell Carcinoma, also known as squamous cell carcinoma of lung, is related to squamous cell carcinoma and adenocarcinoma. An important gene associated with Lung Squamous Cell Carcinoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Endometrial cancer and Downstream signaling events of B Cell Receptor (BCR). The drugs Nedaplatin and afatinib have been mentioned in the context of this disorder. Affiliated tissues include lung, lymph node and endothelial, and related phenotype is pigmentation.

Wikipedia : 73 Squamous-cell carcinoma (SCC) of the lung is a histologic type of non-small-cell lung carcinoma (NSCLC).... more...

Related Diseases for Lung Squamous Cell Carcinoma

Diseases related to Lung Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 360)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 32.7 TUG1 TP53 SOX2-OT PIK3CA FGFR2 EGFR
2 adenocarcinoma 32.0 TP53 PIK3CA KRAS FGFR2 EGFR ALK
3 lung cancer susceptibility 3 31.7 TUG1 TP53 SFTA1P PIK3CA NPTN-IT1 MEG3
4 small cell carcinoma 31.4 TP53 KRAS EGFR ALK
5 retinitis pigmentosa 11 31.3 TP53 PVT1 EGFR ALK
6 in situ carcinoma 31.1 TP53 PIK3CA EGFR
7 small cell cancer of the lung 30.9 TUG1 TP53 PIK3CA EGFR CCAT2
8 pleomorphic carcinoma 30.8 TP53 EGFR ALK
9 lung adenoma 30.8 TP53 KRAS EGFR
10 lung carcinoma in situ 30.8 KRAS EGFR ALK
11 lung non-squamous non-small cell carcinoma 30.8 KRAS EGFR ALK
12 lung benign neoplasm 30.8 TP53 KRAS EGFR
13 adenosquamous carcinoma 30.7 TP53 PIK3CA KRAS EGFR
14 thyroid gland anaplastic carcinoma 30.7 TP53 PIK3CA EGFR ALK
15 pancreatic ductal adenocarcinoma 30.7 TP53 PVT1 KRAS EGFR
16 breast adenocarcinoma 30.6 TP53 PIK3CA KRAS EGFR
17 kidney cancer 30.6 TP53 PVT1 PIK3CA MEG3 EGFR
18 skin melanoma 30.6 TP53 PIK3CA KRAS EGFR ALK
19 intrahepatic cholangiocarcinoma 30.6 TUG1 TP53 KRAS FGFR2 EGFR CCAT2
20 adenoid cystic carcinoma 30.6 TP53 PIK3CA KRAS EGFR
21 cholangiocarcinoma 30.6 TUG1 TP53 SOX2-OT PIK3CA KRAS FGFR2
22 neuroblastoma 30.6 TP53 SNHG1 PIK3CA MEG3 EGFR ALK
23 glioblastoma 30.5 TUG1 TP53 PIK3CA MEG3 FGFR2 EGFR
24 colon adenocarcinoma 30.5 TP53 PIK3CA KRAS EGFR
25 glioma 30.5 TP53 PVT1 PIK3CA MEG3 FGFR2 EGFR
26 colorectal adenocarcinoma 30.5 TP53 KRAS EGFR
27 leukemia, acute myeloid 30.5 TUG1 TP53 PIK3CA MEG3 KRAS EGFR
28 nasopharyngeal carcinoma 30.4 TP53 PVT1 PIK3CA NPTN-IT1 MEG3 FGFR2
29 renal cell carcinoma, nonpapillary 30.4 TUG1 TP53 PVT1 PIK3CA NPTN-IT1 EGFR
30 lung cancer 30.3 TUG1 TP53 TERC SOX2-OT SNHG1 PVT1
31 gastric cancer 30.0 TUG1 TP53 TERC SOX2-OT SNHG1 SFTA1P
32 lung occult squamous cell carcinoma 11.3
33 lung mixed small cell and squamous cell carcinoma 11.3
34 adult teratoma 10.6 TP53 FGFR2
35 esophagus adenocarcinoma 10.6 TP53 FGFR2 EGFR
36 esophagus verrucous carcinoma 10.6 TP53 EGFR
37 signet ring lung adenocarcinoma 10.6 EGFR ALK
38 endometrial adenocarcinoma 10.6 TP53 KRAS FGFR2 EGFR
39 pancreatic signet ring cell adenocarcinoma 10.6 TP53 KRAS
40 esophageal basaloid squamous cell carcinoma 10.6 TP53 EGFR
41 skin papilloma 10.6 TP53 KRAS EGFR
42 acanthoma 10.5 TP53 PIK3CA FGFR2
43 respiratory system benign neoplasm 10.5 TP53 KRAS EGFR
44 bile duct adenocarcinoma 10.5 TP53 KRAS FGFR2 EGFR
45 pulmonary blastoma 10.5 TP53 KRAS EGFR
46 frontal lobe neoplasm 10.5 TP53 EGFR
47 vulvar disease 10.5 TP53 PIK3CA EGFR
48 paronychia 10.5 KRAS EGFR ALK
49 estrogen-receptor positive breast cancer 10.5 TP53 PIK3CA FGFR2 EGFR
50 pulmonary adenocarcinoma in situ 10.5 KRAS EGFR ALK

Graphical network of the top 20 diseases related to Lung Squamous Cell Carcinoma:



Diseases related to Lung Squamous Cell Carcinoma

Symptoms & Phenotypes for Lung Squamous Cell Carcinoma

MGI Mouse Phenotypes related to Lung Squamous Cell Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 pigmentation MP:0001186 9.02 ALK EGFR FGFR2 KRAS TP53

Drugs & Therapeutics for Lung Squamous Cell Carcinoma

Drugs for Lung Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 123)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nedaplatin Approved, Investigational Phase 4 95734-82-0
2
afatinib Approved Phase 4 850140-72-6, 439081-18-2 10184653
3
Apatinib Phase 4 811803-05-1
4
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
5
Etoposide Approved Phase 3 33419-42-0 36462
6
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
7
Vinblastine Approved Phase 3 865-21-4 241903 13342
8
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
9
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
10
Durvalumab Approved, Investigational Phase 2, Phase 3 1428935-60-7
11
Ipilimumab Approved Phase 3 477202-00-9
12
Palbociclib Approved, Investigational Phase 2, Phase 3 571190-30-2 5005498 5330286 11431660
13
Lenograstim Approved, Investigational Phase 3 135968-09-1
14
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
15
Thalidomide Approved, Investigational, Withdrawn Phase 3 50-35-1 5426
16
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
17
Tirapazamine Investigational Phase 3 27314-97-2
18
Iniparib Investigational Phase 3 160003-66-7
19
Rilotumumab Investigational Phase 2, Phase 3 872514-65-3
20 Alkylating Agents Phase 3
21 Etoposide phosphate Phase 3
22 Endostatins Phase 3 71581480
23 Hematinics Phase 3
24 Epoetin alfa Phase 3 113427-24-0
25 Immunoglobulin G Phase 2, Phase 3
26 Protein Kinase Inhibitors Phase 2, Phase 3
27 Antineoplastic Agents, Immunological Phase 2, Phase 3
28
Erlotinib Hydrochloride Phase 2, Phase 3 183319-69-9 176871
29 Immunoglobulins Phase 2, Phase 3
30 Antibodies Phase 2, Phase 3
31 Immunoglobulins, Intravenous Phase 2, Phase 3
32 Antibodies, Monoclonal Phase 2, Phase 3
33 Analgesics, Non-Narcotic Phase 3
34 Cyclooxygenase 2 Inhibitors Phase 3
35 Cyclooxygenase Inhibitors Phase 3
36 Analgesics Phase 3
37 Antirheumatic Agents Phase 3
38 Anti-Inflammatory Agents, Non-Steroidal Phase 3
39 Anti-Bacterial Agents Phase 3
40
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
41
Clarithromycin Approved Phase 2 81103-11-9 84029
42
Treosulfan Approved, Investigational Phase 2 299-75-2 9296
43
Pioglitazone Approved, Investigational Phase 2 111025-46-8 4829
44
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
45
Darbepoetin alfa Approved, Investigational Phase 2 209810-58-2, 11096-26-7
46
Fluoxetine Approved, Vet_approved Phase 2 54910-89-3 3386
47
Isotretinoin Approved Phase 2 4759-48-2 5282379 5538
48
Zileuton Approved, Investigational, Withdrawn Phase 2 111406-87-2 60490
49
Cobalt Approved, Experimental Phase 2 7440-48-4 104729
50
Lomustine Approved, Investigational Phase 2 13010-47-4 3950

Interventional clinical trials:

(show top 50) (show all 177)
# Name Status NCT ID Phase Drugs
1 Apatinib Mesylate Was Used in the Treament of Patients With Advanced Lung Squamous Cell Carcinoma of the Third Line and Above Unknown status NCT03725423 Phase 4 Apatinib
2 Nedaplatin (Jiebaishu®) and Docetaxel in Comparison With Cisplatin and Docetaxel Regimen for the First Line Treatment of Advanced Squamous Cell Carcinoma of Lung(IIIB/IV): Randomized, Controlled, Multicentre Study Completed NCT02088515 Phase 4 Nedaplatin;Cisplatin;Docetaxel
3 An Open-label, Single-arm Clinical Study to Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation Recruiting NCT04132102 Phase 4 Afatinib
4 A Randomized, Phase III Trial of Prophylactic Cranial Irradiation (PCI) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Are Nonprogressive on Gefitinib or Erlotinib Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
5 Evaluation of the Benefits of Oral Metronomic Cyclophosphamide in Combination With Standard Cisplatin-etoposide Based Chemotherapy for Squamous Cell Lung Carcinoma Unknown status NCT01947062 Phase 3 Intravenous Cisplatin & etoposide;Intravenous Cisplatin & etoposide along with oral cyclophosphamide
6 The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration. Unknown status NCT02283476 Phase 3 Endostar continuous intravenous infusion;Endostar routine intravenous infusion;Gemcitabine;Cisplatin
7 Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer :A Randomized, Open, Parallel, Multicentre, Phase Ⅲ Study Unknown status NCT02643407 Phase 3 Docetaxel;Nedaplatin;Cisplatin
8 Phase III Randomized Comparison Study of Vinorelbine, Gemcitabine, and Docetaxel Versus Paclitaxel and Carboplatin in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00079287 Phase 3 carboplatin;docetaxel;gemcitabine hydrochloride;paclitaxel;vinorelbine tartrate
9 Randomized Phase III Trial Of Carboplatin And Paclitaxel Plus Tirapazamine Versus Carboplatin And Paclitaxel In Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00006484 Phase 3 carboplatin;paclitaxel;tirapazamine
10 Concurrent Carboplatin, Paclitaxel, and Radiation Therapy Versus Induction Carboplatin and Paclitaxel Followed by Concurrent Carboplatin, Paclitaxel and Radiation Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer: A Phase III Trial Completed NCT00003387 Phase 3 carboplatin;chemotherapy;paclitaxel
11 A Phase III Randomized Trial Evaluating the Effect of Epoetin Alfa (Procrit) on Local Control in Patients Undergoing Concurrent Chemotherapy and Radiation Therapy for Non-Small Cell Lung Cancer Completed NCT00028938 Phase 3 carboplatin;paclitaxel
12 Randomized Trial of Mediastinal Lymph Node Sampling Versus Complete Lymphadenectomy During Pulmonary Resection in the Patient With N0 and N1 (Less Than Hilar) Non-Small Cell Carcinoma Completed NCT00003831 Phase 3
13 A Prospective Study of the Prognostic Significance of Occult Metastases in the Patient With Resectable Non-Small Cell Lung Carcinoma Completed NCT00003901 Phase 3
14 A Phase III Comparison Between Concurrent Chemotherapy Plus Radiotherapy and Concurrent Chemotherapy Plus Radiotherapy Followed by Surgical Resection for Stage IIIA (N2) Non-Small Cell Lung Cancer Completed NCT00002550 Phase 3 cisplatin;etoposide
15 A Phase III Trial of Single Versus Fractionated Thoracic Radiation for Palliation of Symptoms in Patients With Non-Small Cell Lung Cancer Completed NCT00003685 Phase 3
16 Single-Agent Versus Combination Chemotherapy in Advanced NSCLC: A CALGB Randomized Trial of Efficacy, Quality of Life, and Cost-Effectiveness Completed NCT00003117 Phase 3 carboplatin;paclitaxel
17 A Phase III Trial of Induction Paclitaxel and Carboplatin Followed By Standard Radiotherapy (64 Gy/7 Weeks) vs. Hyperfractionated Accelerated Radiotherapy (HART 57.6 Gy/2.5 Weeks) For Patients With Unresectable Stage IIIA and IIIB Non-Small Cell Lung Cancer Completed NCT00003235 Phase 3 carboplatin;paclitaxel
18 A LARGE-SCALE TRIAL EVALUATING ADJUVANT CHEMOTHERAPY AFTER CURATIVE RESECTION OF NON-SMALL CELL LUNG CANCER Completed NCT00002823 Phase 3 cisplatin;etoposide;vinblastine sulfate;vindesine;vinorelbine tartrate
19 RANDOMIZED TRIAL OF SURGERY VERSUS RADIOTHERAPY IN PATIENTS WITH STAGE IIIa NON-SMALL CELL LUNG CANCER AFTER A RESPONSE TO INDUCTION-CHEMOTHERAPY Completed NCT00002623 Phase 3 carboplatin;cisplatin
20 Randomized Phase 3 Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC) Completed NCT01082549 Phase 3 gemcitabine/carboplatin;gemcitabine/carboplatin plus Iniparib
21 Phase III Study to Evaluate the Optimal Timing of Postoperative Radiotherapy for High Risk of Locoregional Recurrence Patients With Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer Recruiting NCT02974426 Phase 3 Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
22 Preoperative Chemoradiotherapy vs. Chemotherapy Alone in Non-small Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases (Stage IIIA, N2): A Randomized Prospective Phase III Trial Active, not recruiting NCT00030771 Phase 3 Chemotherapy
23 A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer Active, not recruiting NCT00499330 Phase 3
24 A Phase II Study of MEDI4736 for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers (Lung-Map Sub-Study) Active, not recruiting NCT02766335 Phase 2, Phase 3 Docetaxel
25 A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study) Active, not recruiting NCT02785952 Phase 3
26 Efficacy and Safety Evaluation of IBI308 Versus Docetaxel in Patients With Advanced or Metastatic Squamous Cell Lung Cancer After Failure of First-line Platinum-based Therapy- a Randomized, Open-label, Multicenter, Parallel, Phase 3 Study (ORIENT-3) Active, not recruiting NCT03150875 Phase 3 Docetaxel
27 A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study) Active, not recruiting NCT02785939 Phase 2, Phase 3 Docetaxel;Palbociclib
28 A Phase II Study of AZD4547 for Previously Treated FGFR-Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study) Active, not recruiting NCT02965378 Phase 2, Phase 3 Docetaxel;FGFR Inhibitor AZD4547
29 Phase III Randomized Trial of Preoperative Chemotherapy Versus Preoperative Concurrent Chemotherapy and Thoracic Radiotherapy Followed by Surgical Resection and Consolidation Chemotherapy in Favorable Prognosis Patients With Stage IIIA (N2) Non-Small Cell Lung Cancer Terminated NCT00113386 Phase 3 cisplatin;docetaxel
30 A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer Terminated NCT01041781 Phase 3 carboplatin;celecoxib;gemcitabine hydrochloride;pemetrexed disodium
31 A Randomized Phase III Trial of Carboplatin, Paclitaxel and Thoracic Radiotherapy, With or Without Thalidomide, in Patients With Stage III Non-Small Cell Lung Cancer (NSCLC) Terminated NCT00004859 Phase 3 carboplatin;paclitaxel;thalidomide
32 A Randomized Phase III Trial of Adjuvant Chemotherapy in Patients With Early Stage Non-Small Cell Lung Cancer Associated With Banking of Frozen Tumor Specimens and Collection of Gene Expression Profile Data Terminated NCT00863512 Phase 3 cisplatin;docetaxel;gemcitabine hydrochloride;pemetrexed disodium;vinorelbine tartrate
33 A Phase II/III Randomized Study of Rilotumumab Plus Erlotinib Versus Erlotinib as Second Line Therapy for C-Met Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study) Terminated NCT02926638 Phase 2, Phase 3 Erlotinib Hydrochloride
34 A Phase III Randomized, Open-Label Comparative Study of Induction Chemotherapy Followed by Thoracic Radiation Therapy With Supplemental Oxygen, With or Without Concurrent RSR13 (Efaproxiral), in Patients With Locally Advanced Unresectable (Stage IIIA/IIIB) Non-Small Cell Lung Cancer Withdrawn NCT00055887 Phase 3 carboplatin;cisplatin;efaproxiral;gemcitabine hydrochloride;paclitaxel;vinorelbine ditartrate
35 A Randomized, Phase III Multicenter Trial Of Gemcitabine In Combination With Carboplatin Or Paclitaxel Plus Carboplatin In Patients With Metastatic (Stage IIIB, IV) Non-Small Cell Lung Cancer Withdrawn NCT00054392 Phase 3 carboplatin;gemcitabine hydrochloride;paclitaxel
36 Photodynamic Therapy for the Prevention of Lung Cancer (PEARL) Withdrawn NCT03346304 Phase 2, Phase 3
37 A Phase II Multicenter Study Of Lometrexol Sodium And Folic Acid In Subjects With Previously Treated Stage IIIB or IV Non-Small Cell Lung Cancer Unknown status NCT00033722 Phase 2 lometrexol
38 First Line Treatment of Stage IIIb/IV Non Small Cell (NSC) Lung Cancer With a Bimonthly Administration of a Combination of Cisplatin-Gemcitabine Unknown status NCT00006116 Phase 2 cisplatin;gemcitabine hydrochloride
39 A Randomized Phase II Study of Preoperative Versus Postoperative Gemcitabine and Cisplatin for Patients With Stage IB-II Non-Small Cell Lung Cancer Unknown status NCT00398385 Phase 2 cisplatin;gemcitabine hydrochloride
40 Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer Unknown status NCT00979212 Phase 2 panitumumab;carboplatin;paclitaxel
41 Phase II Study Of Gemcitabine And Docetaxel In Patients With Inoperable Stage IIIB Or IIIB or IV Non-Small Cell Lung Cancer Unknown status NCT00075517 Phase 2 docetaxel;gemcitabine hydrochloride
42 A Phase II Study of Non-Small Cell Cancer of the Lung Utilizing Low-Dose Weekly Therapy of Taxotere and Carboplatin Unknown status NCT00003562 Phase 2 carboplatin;docetaxel
43 Boanmycin Hydrochloride for Injection in Combination With Docetaxel for Patients With Advanced Lung Squamous Cell Carcinoma as Salvage Chemotherapy: a Prospective, Randomized, Parallel and Controlled Clinical Trial Unknown status NCT01660399 Phase 2 Boanmycin;Docetaxel
44 A Phase I/II Study of Anlotinib Combined With Platinum-based Chemotherapy as the First-line Treatment of Patients With Locally Advanced or Advanced Non-Small Cell Lung Cancer Unknown status NCT03636685 Phase 1, Phase 2 Anlotinib combined with pemetrexed and carboplatin, phase I;Anlotinib combined with paclitaxel and carboplatin, phase I;Anlotinib combined with pemetrexed and carboplatin, phase II;Anlotinib combined with paclitaxel and carboplatin, phase II
45 A Prospective Phase II, Randomized Multi-center Trial of a Combined Modularized Treatment With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Nivolumab in Patients With Squamous Cell Lung Cancer and Non- Squamous Cell Lung Cancer, Respectively After Platin Failure Unknown status NCT02852083 Phase 2 Pioglitazone;nivolumab;Treosulfan;Clarithromycin
46 An Open-label, Single-armed Pilot Study to Evaluate the Efficacy of Icotinib in Previously Treated Non/Light-smoking Patients With Squamous Lung Cancer Unknown status NCT02009605 Phase 2 Icotinib
47 A Phase II Trial of Nab-paclitaxel as Second-line Therapy in Locally Advanced or Metastatic Squamous Lung Cancer After Failure of Platinum Doublet (Except Pemetrexed) Therapy Unknown status NCT01969955 Phase 2 nanoparticle albumin-bound paclitaxel
48 Phase II Study of Afatinib Plus Chemotherapy in Patients With Esophageal and Lung Squamous Cell Carcinoma Unknown status NCT03486509 Phase 2 Afatinib
49 A Multicenter Phase II Trial of Induction Nimotuzumab Plus Gemcitabine and Carboplatin Followed by Surgery in Patients With Unresectable Stage III Squamous Cell Lung Carcinoma Unknown status NCT02428764 Phase 2 Nimotuzumab;Gemcitabine;Carboplatin
50 A Phase II Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Every-21-Day Docetaxel Consolidation in Patients With Inoperable Stage IIIA/B Squamous Cell Lung Cancer Unknown status NCT02787473 Phase 2 pemetrexed;cisplatin;docetaxel

Search NIH Clinical Center for Lung Squamous Cell Carcinoma

Genetic Tests for Lung Squamous Cell Carcinoma

Anatomical Context for Lung Squamous Cell Carcinoma

MalaCards organs/tissues related to Lung Squamous Cell Carcinoma:

40
Lung, Lymph Node, Endothelial, T Cells, Thyroid, Prostate, Skin

Publications for Lung Squamous Cell Carcinoma

Articles related to Lung Squamous Cell Carcinoma:

(show top 50) (show all 2016)
# Title Authors PMID Year
1
Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. 61 6
23786770 2013
2
EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. 6 61
20360610 2010
3
Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. 61 6
6695174 1984
4
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 6
26619011 2016
5
MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib. 6
23102728 2013
6
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. 6
22753918 2012
7
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. 6
22328973 2011
8
Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma. 6
20942962 2010
9
LKB1 modulates lung cancer differentiation and metastasis. 6
17676035 2007
10
Functional analysis of Peutz-Jeghers mutations reveals that the LKB1 C-terminal region exerts a crucial role in regulating both the AMPK pathway and the cell polarity. 6
15800014 2005
11
A comparison of serum CYFRA 21-1 and SCC Ag in the diagnosis of squamous cell lung carcinoma. 54 61
8882476 1996
12
Evaluation of the susceptibility and fatality of lung cancer patients towards the COVID-19 infection: A systemic approach through analyzing the ACE2, CXCL10 and their co-expressed genes. 61
33585826 2021
13
Extensive bilateral renal metastases of non-small cell lung carcinoma caused acute kidney injury resulting in end-stage renal disease. 61
33058004 2021
14
Differential MUC22 expression by epigenetic alterations in human lung squamous cell carcinoma and adenocarcinoma. 61
33786615 2021
15
Complete response in a patient with lung cancer suffering from three pembrolizumab-induced immune-related adverse events including retinal vasculitis. 61
33732464 2021
16
Use of four genes in exosomes as biomarkers for the identification of lung adenocarcinoma and lung squamous cell carcinoma. 61
33664813 2021
17
Pentraxin 3 acts as a functional effector of Akt/NF-κB signaling to modulate the progression and cisplatin-resistance in non-small cell lung cancer. 61
33617838 2021
18
CXCR1 correlates to poor outcomes of EGFR-TKI against advanced non-small cell lung cancer by activating chemokine and JAK/STAT pathway. 61
33582208 2021
19
COVID‑19 and SARS‑CoV‑2 host cell entry mediators: Expression profiling of TMRSS4 in health and disease. 61
33649798 2021
20
A novel NECTIN4-NTRK1 fusion identified in a lung squamous cell carcinoma patient with MSI-H. 61
33811536 2021
21
Osimertinib for Lung Squamous Cell Carcinoma: A Case Report and Literature Review. 61
33132329 2021
22
Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based Small Molecules. 61
33730493 2021
23
Tumor-educated platelet SNORD55 as a potential biomarker for the early diagnosis of non-small cell lung cancer. 61
33474827 2021
24
Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases. 61
33710807 2021
25
Recombinant immunotoxin targeting GPC3 is cytotoxic to H446 small cell lung cancer cells. 61
33613711 2021
26
Interferon regulatory factor 6 correlates with the progression of non-small cell lung cancer and can be regulated by miR-320. 61
33772297 2021
27
Deep learning-based six-type classifier for lung cancer and mimics from histopathological whole slide images: a retrospective study. 61
33775248 2021
28
Causal relationships between body mass index, smoking and lung cancer: Univariable and multivariable Mendelian randomization. 61
32914876 2021
29
Endotracheal, Endobronchial, and Vocal Cords Metastases From Lung Cancer Detected by 18F-FDG PET/CT. 61
33443947 2021
30
A Case of Untreated Squamous Cell Lung Carcinoma May Contribute to the Occurrence of Hemophagocytic Syndrome. 61
33775994 2021
31
Transformation from adenocarcinoma to squamous cell lung carcinoma with MET amplification after lorlatinib resistance: A case report. 61
33475256 2021
32
Isolated distal ulnar bone metastasis from lung squamous cell carcinoma: an extremely rare case report. 61
33736505 2021
33
Poly(ADP-ribose) glycohydrolase silencing-mediated H2B expression inhibits benzo(a)pyrene-induced carcinogenesis. 61
33044785 2021
34
A Rare Case of a Metastatic Lung Squamous Cell Carcinoma to the Large Bowel and the Liver. 61
33738176 2021
35
Type 2 diabetes and cancer: an umbrella review of observational and Mendelian randomisation studies. 61
33737302 2021
36
FGFR/RACK1 interacts with MDM2, promotes P53 degradation, and inhibits cell senescence in lung squamous cell carcinoma. 61
33710818 2021
37
A novel KLHL6/KLHL24 intergenic region-NTRK3 fusion in a patient with lung squamous cell carcinoma. 61
33744021 2021
38
The Current Landscape of Immune Checkpoint Blockade in Metastatic Lung Squamous Cell Carcinoma. 61
33807509 2021
39
RNA splicing and aggregate gene expression differences in lung squamous cell carcinoma between patients of West African and European ancestry. 61
33465699 2021
40
Specific Lung Squamous Cell Carcinoma Prognosis-Subtype Distinctions Based on DNA Methylation Patterns. 61
33661858 2021
41
Prognostic significance of eight immune-related genes on survival in patients with lung squamous cell carcinoma. 61
33590774 2021
42
Development of alternative splicing signature in lung squamous cell carcinoma. 61
33772655 2021
43
Relationship between podoplanin-expressing cancer-associated fibroblasts and the immune microenvironment of early lung squamous cell carcinoma. 61
33429158 2021
44
Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations. 61
33796225 2021
45
Homology-Based Image Processing for Automatic Classification of Histopathological Images of Lung Tissue. 61
33801859 2021
46
Recent advances in preclinical models for lung squamous cell carcinoma. 61
33707749 2021
47
GenHITS: A network science approach to driver gene detection in human regulatory network using gene's influence evaluation. 61
33326867 2021
48
The effect of pretreatment BMI on the prognosis and serum immune cells in advanced LSCC patients who received ICI therapy. 61
33663076 2021
49
Use of a skin perforator flap pedicled by the intercostal muscle for reconstruction of a posterior cervical defect. 61
32067755 2021
50
A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis. 61
33549049 2021

Variations for Lung Squamous Cell Carcinoma

ClinVar genetic disease variations for Lung Squamous Cell Carcinoma:

6 (show top 50) (show all 329)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 KRAS NM_004985.5(KRAS):c.34G>C (p.Gly12Arg) SNV Pathogenic 12579 rs121913530 GRCh37: 12:25398285-25398285
GRCh38: 12:25245351-25245351
2 EGFR NM_005228.5(EGFR):c.2492G>A (p.Arg831His) SNV Pathogenic 560007 rs150036236 GRCh37: 7:55259434-55259434
GRCh38: 7:55191741-55191741
3 TP53 NM_000546.5(TP53):c.641A>G (p.His214Arg) SNV Likely pathogenic 376615 rs1057519992 GRCh37: 17:7578208-7578208
GRCh38: 17:7674890-7674890
4 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His) SNV Likely pathogenic 12366 rs28934576 GRCh37: 17:7577120-7577120
GRCh38: 17:7673802-7673802
5 TP53 NM_000546.6(TP53):c.659A>G (p.Tyr220Cys) SNV Likely pathogenic 127819 rs121912666 GRCh37: 17:7578190-7578190
GRCh38: 17:7674872-7674872
6 TP53 NM_000546.6(TP53):c.733G>A (p.Gly245Ser) SNV Likely pathogenic 12365 rs28934575 GRCh37: 17:7577548-7577548
GRCh38: 17:7674230-7674230
7 BRAF NM_001374258.1(BRAF):c.1526G>A (p.Gly509Glu) SNV Likely pathogenic 13974 rs121913355 GRCh37: 7:140481402-140481402
GRCh38: 7:140781602-140781602
8 TP53 NM_000546.5(TP53):c.701A>C (p.Tyr234Ser) SNV Likely pathogenic 376690 rs587780073 GRCh37: 17:7577580-7577580
GRCh38: 17:7674262-7674262
9 TP53 NM_000546.5(TP53):c.526T>A (p.Cys176Ser) SNV Likely pathogenic 376570 rs967461896 GRCh37: 17:7578404-7578404
GRCh38: 17:7675086-7675086
10 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala) SNV Likely pathogenic 13659 rs121913274 GRCh37: 3:178936092-178936092
GRCh38: 3:179218304-179218304
11 PIK3CA NM_006218.4(PIK3CA):c.1357G>A (p.Glu453Lys) SNV Likely pathogenic 376470 rs1057519925 GRCh37: 3:178928079-178928079
GRCh38: 3:179210291-179210291
12 HRAS , LRRC56 NM_005343.4(HRAS):c.37G>T (p.Gly13Cys) SNV Likely pathogenic 12606 rs104894228 GRCh37: 11:534286-534286
GRCh38: 11:534286-534286
13 FGFR3 NM_000142.5(FGFR3):c.742C>T (p.Arg248Cys) SNV Likely pathogenic 16332 rs121913482 GRCh37: 4:1803564-1803564
GRCh38: 4:1801837-1801837
14 PTPN11 NM_002834.4(PTPN11):c.226G>A (p.Glu76Lys) SNV Likely pathogenic 13336 rs121918464 GRCh37: 12:112888210-112888210
GRCh38: 12:112450406-112450406
15 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp) SNV Likely pathogenic 12347 rs121912651 GRCh37: 17:7577539-7577539
GRCh38: 17:7674221-7674221
16 EGFR-AS1 , EGFR NM_005228.5(EGFR):c.2303G>T (p.Ser768Ile) SNV Likely pathogenic 45251 rs121913465 GRCh37: 7:55249005-55249005
GRCh38: 7:55181312-55181312
17 PTEN NM_000314.7(PTEN):c.389G>A (p.Arg130Gln) SNV Likely pathogenic 7829 rs121909229 GRCh37: 10:89692905-89692905
GRCh38: 10:87933148-87933148
18 TP53 NM_000546.6(TP53):c.451C>T (p.Pro151Ser) SNV Likely pathogenic 12370 rs28934874 GRCh37: 17:7578479-7578479
GRCh38: 17:7675161-7675161
19 TP53 NM_000546.6(TP53):c.583A>T SNV Likely pathogenic 376617 rs942158624 GRCh37: 17:7578266-7578266
GRCh38: 17:7674948-7674948
20 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln) SNV Likely pathogenic 12356 rs11540652 GRCh37: 17:7577538-7577538
GRCh38: 17:7674220-7674220
21 CREBBP NM_004380.3(CREBBP):c.4336C>T (p.Arg1446Cys) SNV Likely pathogenic 95047 rs398124146 GRCh37: 16:3788618-3788618
GRCh38: 16:3738617-3738617
22 PIK3CA NM_006218.4(PIK3CA):c.1258T>C (p.Cys420Arg) SNV Likely pathogenic 31945 rs121913272 GRCh37: 3:178927980-178927980
GRCh38: 3:179210192-179210192
23 TP53 NM_000546.5(TP53):c.332T>A (p.Leu111Gln) SNV Likely pathogenic 376632 rs1057519997 GRCh37: 17:7579355-7579355
GRCh38: 17:7676037-7676037
24 TP53 NM_000546.5(TP53):c.584T>A (p.Ile195Asn) SNV Likely pathogenic 376618 rs760043106 GRCh37: 17:7578265-7578265
GRCh38: 17:7674947-7674947
25 TP53 NM_000546.5(TP53):c.746G>C (p.Arg249Thr) SNV Likely pathogenic 376015 rs587782329 GRCh37: 17:7577535-7577535
GRCh38: 17:7674217-7674217
26 TP53 NM_001276697.2(TP53):c.-75T>A SNV Likely pathogenic 376562 rs1057519975 GRCh37: 17:7578527-7578527
GRCh38: 17:7675209-7675209
27 TP53 NM_000546.5(TP53):c.647T>G (p.Val216Gly) SNV Likely pathogenic 376671 rs1057520004 GRCh37: 17:7578202-7578202
GRCh38: 17:7674884-7674884
28 TP53 NM_000546.5(TP53):c.536A>G (p.His179Arg) SNV Likely pathogenic 376606 rs1057519991 GRCh37: 17:7578394-7578394
GRCh38: 17:7675076-7675076
29 TP53 NM_000546.6(TP53):c.396G>C (p.Lys132Asn) SNV Likely pathogenic 376624 rs866775781 GRCh37: 17:7578534-7578534
GRCh38: 17:7675216-7675216
30 TP53 NM_000546.6(TP53):c.523C>T (p.Arg175Cys) SNV Likely pathogenic 245851 rs138729528 GRCh37: 17:7578407-7578407
GRCh38: 17:7675089-7675089
31 TP53 NM_000546.5(TP53):c.646G>T (p.Val216Leu) SNV Likely pathogenic 376670 rs730882025 GRCh37: 17:7578203-7578203
GRCh38: 17:7674885-7674885
32 TP53 NM_000546.5(TP53):c.373A>C (p.Thr125Pro) SNV Likely pathogenic 376666 rs1057520003 GRCh37: 17:7579314-7579314
GRCh38: 17:7675996-7675996
33 TP53 NM_000546.5(TP53):c.746G>T (p.Arg249Met) SNV Likely pathogenic 376653 rs587782329 GRCh37: 17:7577535-7577535
GRCh38: 17:7674217-7674217
34 TP53 NM_000546.5(TP53):c.658T>A (p.Tyr220Asn) SNV Likely pathogenic 376688 rs530941076 GRCh37: 17:7578191-7578191
GRCh38: 17:7674873-7674873
35 TP53 NM_000546.5(TP53):c.724T>A (p.Cys242Ser) SNV Likely pathogenic 376579 rs1057519982 GRCh37: 17:7577557-7577557
GRCh38: 17:7674239-7674239
36 CDKN2A NM_000077.4(CDKN2A):c.292C>T (p.His98Tyr) SNV Likely pathogenic 419560 rs1064793953 GRCh37: 9:21971066-21971066
GRCh38: 9:21971067-21971067
37 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys) SNV Likely pathogenic 13655 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303
38 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg) SNV Likely pathogenic 13652 rs121913279 GRCh37: 3:178952085-178952085
GRCh38: 3:179234297-179234297
39 PIK3CA NM_006218.4(PIK3CA):c.1624G>A (p.Glu542Lys) SNV Likely pathogenic 31944 rs121913273 GRCh37: 3:178936082-178936082
GRCh38: 3:179218294-179218294
40 TP53 NM_000546.5(TP53):c.487T>C (p.Tyr163His) SNV Likely pathogenic 376680 rs786203436 GRCh37: 17:7578443-7578443
GRCh38: 17:7675125-7675125
41 FGFR3 NM_001163213.1(FGFR3):c.746C>G (p.Ser249Cys) SNV Likely pathogenic 16339 rs121913483 GRCh37: 4:1803568-1803568
GRCh38: 4:1801841-1801841
42 TP53 NM_000546.5(TP53):c.832C>G (p.Pro278Ala) SNV Likely pathogenic 376645 rs17849781 GRCh37: 17:7577106-7577106
GRCh38: 17:7673788-7673788
43 TP53 NM_000546.5(TP53):c.700T>A (p.Tyr234Asn) SNV Likely pathogenic 376692 rs864622237 GRCh37: 17:7577581-7577581
GRCh38: 17:7674263-7674263
44 TP53 NM_001126115.1(TP53):c.-3A>C SNV Likely pathogenic 376628 rs747342068 GRCh37: 17:7578536-7578536
GRCh38: 17:7675218-7675218
45 TP53 NM_000546.5(TP53):c.833C>T (p.Pro278Leu) SNV Likely pathogenic 232497 rs876659802 GRCh37: 17:7577105-7577105
GRCh38: 17:7673787-7673787
46 TP53 NM_000546.5(TP53):c.526T>C (p.Cys176Arg) SNV Likely pathogenic 376573 rs967461896 GRCh37: 17:7578404-7578404
GRCh38: 17:7675086-7675086
47 TP53 NM_000546.5(TP53):c.585C>G (p.Ile195Met) SNV Likely pathogenic 376620 rs1057519994 GRCh37: 17:7578264-7578264
GRCh38: 17:7674946-7674946
48 TP53 NM_000546.5(TP53):c.832C>T (p.Pro278Ser) SNV Likely pathogenic 376642 rs17849781 GRCh37: 17:7577106-7577106
GRCh38: 17:7673788-7673788
49 TP53 NM_000546.5(TP53):c.709A>G (p.Met237Val) SNV Likely pathogenic 182934 rs730882004 GRCh37: 17:7577572-7577572
GRCh38: 17:7674254-7674254
50 PIK3CA NM_006218.4(PIK3CA):c.452T>C (p.Val151Ala) SNV Likely pathogenic 873163 GRCh37: 3:178917577-178917577
GRCh38: 3:179199789-179199789

Cosmic variations for Lung Squamous Cell Carcinoma:

9 (show top 50) (show all 46804)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88263727 ZRSR2 lung,NS,carcinoma,adenocarcinoma c.937+1G>T p.? 23:15820317-15820317 21
2 COSM101712070 ZRANB3 lung,NS,carcinoma,squamous cell carcinoma c.3171G>C p.V1057= 2:135200405-135200405 21
3 COSM131775319 ZRANB3 lung,NS,carcinoma,squamous cell carcinoma c.1815G>C p.V605= 2:135200405-135200405 21
4 COSM87596300 ZRANB3 lung,NS,carcinoma,squamous cell carcinoma c.3177G>C p.V1059= 2:135200405-135200405 21
5 COSM142228089 ZRANB3 lung,NS,carcinoma,squamous cell carcinoma c.1566G>C p.V522= 2:135200405-135200405 21
6 COSM142168947 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.-18G>C p.? 7:89218278-89218278 21
7 COSM92052275 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.1662G>T p.L554F 7:89334644-89334644 21
8 COSM142179137 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.3235C>T p.Q1079* 7:89336466-89336466 21
9 COSM142183562 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.1361A>G p.K454R 7:89334592-89334592 21
10 COSM142180477 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.1413G>T p.L471F 7:89334644-89334644 21
11 COSM142169111 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.494G>A p.C165Y 7:89333725-89333725 21
12 COSM142178407 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.734A>G p.N245S 7:89333965-89333965 21
13 COSM92062218 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.1610A>G p.K537R 7:89334592-89334592 21
14 COSM92044981 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.983A>G p.N328S 7:89333965-89333965 21
15 COSM92017258 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.743G>A p.C248Y 7:89333725-89333725 21
16 COSM92016873 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.232G>C p.D78H 7:89218278-89218278 21
17 COSM92047471 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.3484C>T p.Q1162* 7:89336466-89336466 21
18 COSM88573896 ZNF804A lung,NS,carcinoma,squamous cell carcinoma c.163G>T p.A55S 2:184866420-184866420 21
19 COSM143615263 ZNF804A lung,NS,carcinoma,squamous cell carcinoma c.-93G>T p.? 2:184866420-184866420 21
20 COSM135196993 ZNF598 lung,NS,carcinoma,squamous cell carcinoma c.386G>A p.R129H 16:2002647-2002647 21
21 COSM137961812 ZNF598 lung,NS,carcinoma,squamous cell carcinoma c.386G>A p.R129H 16:2002647-2002647 21
22 COSM94776745 ZNF521 lung,NS,carcinoma,squamous cell carcinoma c.934T>A p.C312S 18:25226984-25226984 21
23 COSM131483085 ZNF521 lung,NS,carcinoma,squamous cell carcinoma c.934T>A p.C312S 18:25226984-25226984 21
24 COSM140721616 ZNF521 lung,NS,carcinoma,squamous cell carcinoma c.757C>T p.P253S 18:25226501-25226501 21
25 COSM94799739 ZNF521 lung,NS,carcinoma,squamous cell carcinoma c.1417C>T p.P473S 18:25226501-25226501 21
26 COSM131506553 ZNF521 lung,NS,carcinoma,squamous cell carcinoma c.1417C>T p.P473S 18:25226501-25226501 21
27 COSM140704568 ZNF521 lung,NS,carcinoma,squamous cell carcinoma c.274T>A p.C92S 18:25226984-25226984 21
28 COSM89756750 ZNF479 lung,NS,carcinoma,squamous cell carcinoma c.1064G>T p.C355F 7:57120351-57120351 21
29 COSM144163369 ZNF479 lung,NS,carcinoma,squamous cell carcinoma c.779+33G>T p.? 7:57120351-57120351 21
30 COSM90068315 ZNF479 lung,NS,carcinoma,squamous cell carcinoma c.1064G>T p.C355F 7:57120351-57120351 21
31 COSM106286350 ZNF331 lung,NS,carcinoma,squamous cell carcinoma c.108G>T p.L36= 19:53571702-53571702 21
32 COSM112397402 ZNF331 lung,NS,carcinoma,squamous cell carcinoma c.108G>T p.L36= 19:53571702-53571702 21
33 COSM123216142 ZNF331 lung,NS,carcinoma,squamous cell carcinoma c.108G>T p.L36= 19:53571702-53571702 21
34 COSM125618139 ZNF331 lung,NS,carcinoma,squamous cell carcinoma c.108G>T p.L36= 19:53571702-53571702 21
35 COSM124797288 ZNF331 lung,NS,carcinoma,squamous cell carcinoma c.108G>T p.L36= 19:53571702-53571702 21
36 COSM122109165 ZNF331 lung,NS,carcinoma,squamous cell carcinoma c.108G>T p.L36= 19:53571702-53571702 21
37 COSM86289413 ZNF331 lung,NS,carcinoma,squamous cell carcinoma c.108G>T p.L36= 19:53571702-53571702 21
38 COSM124886437 ZNF331 lung,NS,carcinoma,squamous cell carcinoma c.108G>T p.L36= 19:53571702-53571702 21
39 COSM95442728 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.128A>G p.N43S 3:50345197-50345197 21
40 COSM85262562 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.622C>T p.R208C 3:50342996-50342996 21
41 COSM85263435 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.128A>G p.N43S 3:50345197-50345197 21
42 COSM95441934 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.599+122C>T p.? 3:50342996-50342996 21
43 COSM101607526 ZMYM2 lung,NS,carcinoma,squamous cell carcinoma c.1484G>T p.C495F 13:20006558-20006558 21
44 COSM143112283 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.94G>A p.G32R 13:19993166-19993166 21
45 COSM101592316 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.94G>A p.G32R 13:19993166-19993166 21
46 COSM101606460 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 21
47 COSM101614868 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.369G>C p.E123D 13:19993441-19993441 21
48 COSM101585076 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 21
49 COSM101586020 ZMYM2 lung,NS,carcinoma,squamous cell carcinoma c.1484G>T p.C495F 13:20006558-20006558 21
50 COSM101614672 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.94G>A p.G32R 13:19993166-19993166 21

Copy number variations for Lung Squamous Cell Carcinoma from CNVD:

7 (show top 50) (show all 61)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13957 1 101664084 102994090 Loss COL11A1 Lung squamous cell carcinoma
2 18603 1 146800000 147200000 Loss Lung squamous cell carcinoma
3 18604 1 146800000 147200000 Loss NBPF15 Lung squamous cell carcinoma
4 18605 1 146800000 147200000 Loss NBPF15 Lung squamous cell carcinoma
5 18606 1 146800000 147200000 Loss PPIAL4E Lung squamous cell carcinoma
6 47066 10 89540134 89615643 Loss PTEN Lung squamous cell carcinoma
7 51887 11 132926079 134452384 Loss ACAD8 Lung squamous cell carcinoma
8 58625 11 68821296 70110392 Gain CCND1 Lung squamous cell carcinoma
9 58626 11 68821296 70110392 Gain PPFIA1 Lung squamous cell carcinoma
10 79487 13 72396304 72490843 Loss Lung squamous cell carcinoma
11 89148 15 100100000 100300000 Loss OR4F15 Lung squamous cell carcinoma
12 89149 15 100100000 100300000 Loss OR4F4 Lung squamous cell carcinoma
13 89150 15 100100000 100300000 Loss OR4F6 Lung squamous cell carcinoma
14 105616 16 80626349 81449546 Loss Lung squamous cell carcinoma
15 107157 17 12394069 12459756 Loss Lung squamous cell carcinoma
16 118123 17 7571720 7590868 Mutation TP53 Lung squamous cell carcinoma
17 122933 18 64017241 75522477 Loss CD226 Lung squamous cell carcinoma
18 122934 18 64017241 75522477 Loss MBP Lung squamous cell carcinoma
19 122935 18 64017241 75522477 Loss RTTN Lung squamous cell carcinoma
20 122936 18 64017241 75522477 Loss SOCS6 Lung squamous cell carcinoma
21 128995 19 43840068 44336812 Gain AKT2 Lung squamous cell carcinoma
22 128996 19 43840068 44336812 Gain ECH1 Lung squamous cell carcinoma
23 130187 19 47900000 48300000 Loss PSG1 Lung squamous cell carcinoma
24 130188 19 47900000 48300000 Loss PSG11 Lung squamous cell carcinoma
25 130189 19 47900000 48300000 Loss PSG2 Lung squamous cell carcinoma
26 130190 19 47900000 48300000 Loss PSG3 Lung squamous cell carcinoma
27 130191 19 47900000 48300000 Loss PSG6 Lung squamous cell carcinoma
28 130192 19 47900000 48300000 Loss PSG7 Lung squamous cell carcinoma
29 130193 19 47900000 48300000 Loss PSG8 Lung squamous cell carcinoma
30 131640 19 55600000 55700000 Gain ASPDH Lung squamous cell carcinoma
31 131641 19 55600000 55700000 Gain EMC10 Lung squamous cell carcinoma
32 131642 19 55600000 55700000 Gain FAM71E1 Lung squamous cell carcinoma
33 131643 19 55600000 55700000 Gain JOSD2 Lung squamous cell carcinoma
34 131644 19 55600000 55700000 Gain MYBPC2 Lung squamous cell carcinoma
35 131645 19 55600000 55700000 Gain NAPSA Lung squamous cell carcinoma
36 131646 19 55600000 55700000 Gain NR1H2 Lung squamous cell carcinoma
37 131647 19 55600000 55700000 Gain POLD1 Lung squamous cell carcinoma
38 131648 19 55600000 55700000 Gain SPIB Lung squamous cell carcinoma
39 149556 11 35116992 35210525 Loss CD44 Lung squamous cell carcinoma
40 149667 2 91000000 91500000 Loss GGT8P Lung squamous cell carcinoma
41 149668 2 91000000 91500000 Loss Lung squamous cell carcinoma
42 172539 3 183473858 183941579 Gain SOX2 Lung squamous cell carcinoma
43 172540 3 183473858 183941579 Gain TP63 Lung squamous cell carcinoma
44 179006 3 84414538 85858393 Loss POU1F1 Lung squamous cell carcinoma
45 181932 4 130278523 134426567 Loss PLK4 Lung squamous cell carcinoma
46 185649 4 20391110 20848036 Loss BST1 Lung squamous cell carcinoma
47 185650 4 20391110 20848036 Loss PI4K2B Lung squamous cell carcinoma
48 185651 4 20391110 20848036 Loss SLIT2 Lung squamous cell carcinoma
49 191445 5 1 1510601 Gain TERT Lung squamous cell carcinoma
50 202010 5 76066702 76539988 Loss HTR1A Lung squamous cell carcinoma

Expression for Lung Squamous Cell Carcinoma

Search GEO for disease gene expression data for Lung Squamous Cell Carcinoma.

Pathways for Lung Squamous Cell Carcinoma

Pathways related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.72 TP53 PIK3CA KRAS FGFR2 EGFR
2
Show member pathways
12.55 TP53 PIK3CA KRAS FGFR2 EGFR
3
Show member pathways
12.45 TP53 PIK3CA KRAS FGFR2 EGFR
4
Show member pathways
12.4 TP53 TERC PIK3CA KRAS FGFR2 EGFR
5
Show member pathways
12.3 TP53 PIK3CA KRAS FGFR2 EGFR
6
Show member pathways
12.27 TP53 PIK3CA KRAS FGFR2 EGFR
7
Show member pathways
12.24 PIK3CA KRAS FGFR2 EGFR ALK
8
Show member pathways
12.23 TP53 PIK3CA KRAS FGFR2 EGFR ALK
9 12.22 TP53 TERC PIK3CA KRAS FGFR2 EGFR
10
Show member pathways
12.19 TP53 PIK3CA KRAS FGFR2 EGFR
11 12.14 TP53 PIK3CA KRAS EGFR
12
Show member pathways
12.04 TP53 PIK3CA KRAS FGFR2 EGFR
13
Show member pathways
11.71 PIK3CA KRAS EGFR
14 11.58 TP53 KRAS EGFR
15 11.29 KRAS FGFR2 EGFR
16 10.93 PIK3CA KRAS EGFR
17 10.87 TP53 PIK3CA KRAS FGFR2 EGFR
18 10.64 TP53 MEG3

GO Terms for Lung Squamous Cell Carcinoma

Biological processes related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 liver development GO:0001889 9.33 PIK3CA KRAS EGFR
2 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 8.96 TP53 EGFR
3 positive regulation of kinase activity GO:0033674 8.8 FGFR2 EGFR ALK

Molecular functions related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.8 FGFR2 EGFR ALK

Sources for Lung Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....